Botulinum Toxin Injections -- Cosmetic
Botulinum Toxin Injections—Cosmetic
(Botulinum Toxin Type A; Botulinum Toxin Type B; Botox Injections)
|Copyright © Nucleus Medical Media, Inc.|
Reasons for Procedure
- Stinging around the injection sites
- Flu -like symptoms
- Excessive weakness of the muscle around the eyes—can cause drooping of the eyelids or obstruction of vision
- Difficulty swallowing—can occur in patients receiving injections in their neck
FDA Public Health Advisory for Botulinum Toxin
There is a risk that the botulinum toxin could spread beyond the injection area. This can cause botulism symptoms, including difficulty breathing and death. These symptoms appear to be more common in children with cerebral palsy who receive the injection to treat spasticity. The warning is for Botox , Botox Cosmetic, Myobloc , and Dysport. For more information, please visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175013.htm .
- Have an infection or inflammation in the area where botox will be injected
- Are sensitive to the ingredients in botox
- Are pregnant or breastfeeding
What to Expect
Description of the Procedure
- Remain upright for several hours
- Avoid alcohol
How Long Will It Take?
Will It Hurt?
Call Your Doctor
- Difficulty breathing
- Difficulty swallowing
- Difficulty speaking
- Severe lower eyelid droop or obstructed vision
- Excessive weakness around the injection site
- Rash or any other sign of an allergic reaction
American Society for Dermatologic Surgery http://www.asds-net.org/
American Society of Plastic Surgeons http://www.plasticsurgery.org/
Canadian Dermatology Association http://www.dermatology.ca/
Health Canada http://www.hc-sc.gc.ca/
Allergan Physician Production Information. Botox cosmetic (botulinum toxin type A). Published April 2008.
Baran R, Maibach H. Textbook of Cosmetic Dermatology . 3rd ed. New York, NY: Taylor and Francis; 2004.
Conn HF, Rakel R. Conn’s Current Therapy. 54th ed. Philadelphia, PA: WB Saunders Company; 2002.
Habif T. Clinical Dermatology . 4th ed. St. Louis, MO: Mosby; 2004.
Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache . 2005;45(8):1073-1077.
Ward A, Roberts G, Warner J, et al. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med . 2005;37(4):252-257.
11/4/2009 DynaMed Systematic Literature Surveillance DynaMed's Systematic Literature Surveillance : FDA gives update on botulinum toxin safety warnings. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175013.htm . Updated August 3, 2009. Accessed November 4, 2009.
- Reviewer: Marcin Chwistek, MD
- Review Date: 10/2012 -
- Update Date: 10/31/2012 -